Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 232

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 232
---
     |             |   1,401 |     |                            |        972 |     |             |     751 |
| Denominator:                                                 |     |                          |            |     |             |         |     |                            |            |     |             |         |
| Shares of Ordinary Share used in computing basic and diluted 
 net loss per share                                           |     |                          | 60,729,100 |     |             | 143,447 |     |                            | 60,729,100 |     |             | 143,447 |
| Net loss per share of Ordinary Share, basic and diluted      |     |                          |       0.03 |     |             |    9.76 |     |                            |       0.02 |     |             |    5.23 |

<div align='center'>F-41</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

| NOTE 5: - | SHAREHOLDERS’ EQUITY |

On April
8, 2025, Company’s subsidiary Lipovation, by a resolution of its Board of Directors has terminated its share option plan and received
from all option grantees waivers for the cancellation of their options without any claims, rights, obligations, damages and liabilities
of any nature pursuant to the termination of their terminated options. As such, the remaining non controlling interest at the amount
of $809 were classified under additional paid in capital.

Share-based
expenses recognized in the financial statements:

|                                     |     |                Successor |     |     | Predecessor |     |     |                  Successor |     |     | Predecessor |     |
|                                     |     | For the six months ended 
                 June 30, |     |     |             |     |     | For the three months ended 
                   June 30, |     |     |             |     |
|                                     |     |                     2025 |     |     |        2024 |     |     |                       2025 |     |     |        2024 |     |
|                                     |     |                Unaudited |     |     |   Unaudited |     |     |                  Unaudited |     |     |   Unaudited |     |
| Research and development expenses   |     |                          | 103 |     |             | 710 |     |